- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05248230
4D-710 in Adult Patients With Cystic Fibrosis (CF)
January 4, 2024 updated by: 4D Molecular Therapeutics
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults With Cystic Fibrosis
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with CF who are ineligible for or unable to tolerate CFTR modulator therapy.
Study Overview
Detailed Description
This Phase 1/2 trial will evaluate the safety, tolerability, and preliminary efficacy of 4 dose levels of 4D-710, an investigational gene therapy, in adults with cystic fibrosis lung disease who are ineligible or unable to tolerate CFTR modulator therapy.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: 4DMT Patient Advocacy
- Phone Number: (888) 748-8881
- Email: clinicaltrials@4DMT.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama Child Health Research Unit
-
Contact:
- Heather Hathorne
- Email: hyhathorne@uabmc.edu
-
Contact:
- Kathryn Monroe
- Email: kathrynmonroe@uabmc.edu
-
Principal Investigator:
- George M. Solomon, MD
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Recruiting
- National Jewish Health
-
Contact:
- Alexandra Wilson
- Email: wilsona@njhealth.org
-
Contact:
- Jennifer Taylor-Cousar, MD
- Email: TaylorCousarJ@NJHealth.org
-
Principal Investigator:
- Jennifer Taylor-Cousar, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern Memorial Hospital
-
Contact:
- Rachel Nelson
- Email: rachel.nelson@northwestern.edu
-
Principal Investigator:
- Manu Jain, MD
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
Contact:
- Lawrence Scott
- Email: lscott2@kumc.edu
-
Principal Investigator:
- Joel Mermis, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Monica Ulles
- Email: monica.ulles@childrens.harvard.edu
-
Principal Investigator:
- Alicia Casey, MD
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- Allen Lapey, MD
-
Contact:
- Margot Hardcastle
- Email: mhardcastle@mgh.harvard.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- University of North Carolina at Chapel Hill
-
Contact:
- Alexandria Nesbit
- Email: alexandria_nesbit@med.unc.edu
-
Contact:
- Margret Powell
- Email: margret_powell@med.unc.edu
-
Principal Investigator:
- Scott Donaldson, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44146
- Recruiting
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
-
Contact:
- Tia Rone
- Email: Tia.Rone@uhhospitals.org
-
Contact:
- Laura Batke
- Email: Laura.Batke@UHhospitals.org
-
Principal Investigator:
- Alex Gifford, MD
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Principal Investigator:
- Karen S. McCoy, MD
-
Contact:
- Terri Johnson
- Email: terri.johnson@nationwidechildrens.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Health
-
Contact:
- Diane Kitch
- Email: dkitch@pennstatehealth.psu.edu
-
Principal Investigator:
- Judie A. Howrylak, MD, PhD
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- The Hospital of the University of Pennsylvania
-
Contact:
- Melissa Molter
- Email: melissa.molter@pennmedicine.upenn.edu
-
Principal Investigator:
- Daniel Dorgan, MD
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- The University of Texas Southwestern Medical Center
-
Contact:
- Ashley Keller
- Email: Ashley.Keller@UTSouthwestern.edu
-
Principal Investigator:
- Raksha Jain, MD
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University Health System
-
Contact:
- Margaret K. Lessard
- Email: margaret.lessard@vcuhealth.org
-
Principal Investigator:
- Nauman A. Chaudary, MD
-
-
Washington
-
Seattle, Washington, United States, 98195
- Recruiting
- University of Washington Medical Center
-
Principal Investigator:
- Christopher Goss, MD
-
Contact:
- Roshni Prabhu
- Email: rprabhu@medicine.washington.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- 18 years and older
Confirmed diagnosis of cystic fibrosis (CF) and CF lung disease including:
- Sweat chloride ≥ 60 mmol/L
Mutation Status
- Bi-allelic mutations in the CFTR gene, or
- Single mutation in the CFTR gene and clinical manifestations of CF lung disease
- Ineligible for CFTR modulator therapy, or previously received modulator therapy but discontinued due to adverse effects.
- Forced expiratory volume in 1 second (FEV1) ≥50% and ≤100% of predicted (per Global Lung Function Initiative) at Screening
- Resting oxygen saturation ≥ 92% on room air at Screening
Key Exclusion Criteria:
- Any prior gene therapy for any indication (Exception: mRNA-based therapies are not exclusionary)
- Active Mycobacterium abscessus infection requiring ongoing treatment at Screening
- Active allergic bronchopulmonary aspergillosis requiring management with systemic corticosteroids or antifungal therapy
- Two or more pulmonary exacerbations requiring treatment with intravenous (IV) antibiotics within 6 months prior to Screening
- Contraindication to systemic corticosteroid therapy
- Requires chronic use of systemic corticosteroids or immunosuppressants to treat another condition
- If no known diagnosis of cystic fibrosis related diabetes (CFRD), Type I, or Type II diabetes: Hemoglobin A1C ≥6.5% at Screening
- If known diagnosis of CFRD, Type I or Type II diabetes: Hemoglobin A1C >7.5% at Screening
- Recent history of symptomatic hyperglycemia or unstable blood glucose levels as per Investigator's assessment
- Other conditions that, in the Investigator's opinion, may interfere with management of corticosteroid-related hyperglycemia
- Body Mass Index (BMI) <16
Laboratory abnormalities at screening:
- ALT, AST or GGT ≥ 3 × the upper limit of normal (ULN)
- Total bilirubin ≥ 2 × ULN
- Hemoglobin < 10 g/dL
- Requirement for continuous or night-time oxygen supplementation
- Known CF liver disease with evidence of cirrhosis
- History of thrombosis (excluding catheter-related thrombosis) or conditions associated with increased risk of thrombosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 4D-710 Dose Expansion Cohort
Single inhalational administration of 4D-710 at the selected dose
|
4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
|
Experimental: 4D-710 Dose Exploration Cohort 1
Single inhalational administration of 4D-710 Dose 1
|
4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
|
Experimental: 4D-710 Dose Exploration Cohort 2
Single inhalational administration of 4D-710 Dose 2
|
4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
|
Experimental: 4D-710 Dose Exploration Cohort 3
Single inhalational administration of 4D-710 Dose 3
|
4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
|
Experimental: 4D-710 Dose Exploration Cohort 4
Single inhalational administration of 4D-710 Dose 4
|
4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events
Time Frame: 24 Months
|
Safety and tolerability of 4D-710 following a single inhalation dose, as assessed by incidence and severity of treatment emergent adverse events, serious adverse events, and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters.
|
24 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Alan H. Cohen, MD, 4D Molecular Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 29, 2022
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
January 1, 2027
Study Registration Dates
First Submitted
February 10, 2022
First Submitted That Met QC Criteria
February 10, 2022
First Posted (Actual)
February 21, 2022
Study Record Updates
Last Update Posted (Estimated)
January 8, 2024
Last Update Submitted That Met QC Criteria
January 4, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4D-710-C001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis Lung
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Heidelberg UniversityGerman Center for Lung ResearchRecruitingCystic Fibrosis Lung DiseaseGermany
-
University Hospital, BordeauxCompleted
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Heidelberg UniversityGerman Center for Lung ResearchCompletedCystic Fibrosis Lung DiseaseGermany
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationNot yet recruitingCystic Fibrosis in ChildrenUnited States
-
Indiana UniversityCompleted
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
Clinical Trials on 4D-710
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedTumor, SolidUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Liver | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic...United States
-
Assistance Publique Hopitaux De MarseilleCompleted
-
4D Molecular TherapeuticsActive, not recruitingChoroideremiaUnited States
-
University Hospital, MontpellierCompletedPronation-Supination of the Forearm, Impairment ofFrance
-
University of LouisvilleJames Graham Brown Cancer CenterActive, not recruitingLung CancerUnited States
-
Centre Hospitalier Universitaire, AmiensUnknownTetralogy of Fallot | Magnetic Resonance ImagingFrance
-
Yale UniversityCompleted
-
Centre Hospitalier Universitaire, AmiensCompletedPulmonary Hypertension | Magnetic Resonance Imaging | Echocardiography | Right Heart Catheterization | Pulmonary Arterial PressureFrance
-
The Netherlands Cancer InstituteCompleted